Biotech News

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (KALV)KalVista Pharmaceuticals, Inc.2026-05-28 11:00 ESTConference / presentation

Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 28,

KalVista Pharmaceuticals, Inc.

Hereditary Angioedema Company KalVista Pharmaceuticals develops and commercializes therapies for hereditary angioedema. Its lead franchise is based on oral inhibition of plasma kallikrein during acute attacks. EKTERLY EKTERLY, or sebetralstat, is the first approved oral on-demand treatment for hereditary angioedema attacks. It is...

Recent company news

KALVKalVista Pharmaceuticals, Inc.2026-06-11 12:41 EST

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

KALVKalVista Pharmaceuticals, Inc.2026-05-28 11:00 EST